This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV0010

Prevalence and associated factors of benzodiazepine use disorder in patients with acute and chronic lung disease

PREVALENCE AND ASSOCIATED FACTORS OF BENZODIAZEPINE USE DISORDER IN PATIENTS WITH ACUTE AND CHRONIC LUNG DISEASES

One-third of patients with lung disease use benzodiazepines, and 34.5% of users meet the criteria for benzodiazepine use disorder. Poor health-related quality of life, rather than the type of lung disease, independently predicts the disorder.

The aim of the study was to determine the prevalence of benzodiazepine use disorder (BUD) and associated factors in adults with acute and chronic lung disease; the poster states that this is the first study on this topic in Iran. A cross-sectional study was conducted with 332 adults at two tertiary care hospitals; the SF-36 and Katz Index of Independence in Activities of Daily Living were used, and the data were analyzed using logistic regression. Of the patients, 34% (113 individuals) reported benzodiazepine use, and 34.5% of these users (39 individuals) met the criteria for BUD. The BUD rate was 45.1% in women and 23.2% in men, and 43.8% in inpatients and 27.9% in outpatients. No significant association was found between the type of lung disease and BUD; in the multivariable model, lower health-related quality of life (HRQoL) independently predicted BUD (p = 0.024), while male sex was associated with lower odds (p = 0.008); model fit was adequate (omnibus p = 0.001, Hosmer–Lemeshow p = 0.264). In conclusion, poorer quality of life, rather than the type of lung disease, was associated with BUD. These findings support caution when prescribing benzodiazepines, particularly for patients with poor quality of life; limitations include the inability to infer causality due to the cross-sectional design, the restriction of the sample to two centers, and reliance on self-reported benzodiazepine use.

All WCP 2026 summaries